Avita Medical (RCEL)

• Market cap: $309M
• 1 day: 2.53%
• 5 days: -3.68%
• 1 month: -9.81%
• 3 months: 8.28%
• 6 months: 41.81%
• Year to date: -13.33%
• 1 year: -5.31%
• 5 years: 32.25%
• 10 years: 65.31%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Employees: 207

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 16

33% more capital invested

Capital invested by funds: $49.2M [Q2] → $65.3M (+$16.2M) [Q3]

0.61% less ownership

Funds ownership: 24.06% [Q2] → 23.45% (-0.61%) [Q3]

5% less call options, than puts

Call options by funds: $423K | Put options by funds: $447K

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

1% less funds holding

Funds holding: 68 [Q2] → 67 (-1) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12 2% upside
• Avg. target: $12 2% upside
• High target: $12 2% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Piper Sandler Matt O'Brien 58% 1-year accuracy 30 / 52 met price target

2% upside $12

Neutral Reiterated

8 Nov 2024